Revvity (RVTY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.41
- Estimate
- $1.22
- Surprise
- +15.9%
- Score at report (before → after)
- 5.2 → 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Revvity (RVTY) beat the $1.22 estimate with adjusted EPS of $1.41 — a large 15.9% upside surprise. TrendMatrix's engine moved from Hold (5.2/10) to Buy (Wait) at 5.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RVTY Sell at 4.9/10.
4 of the last 4 quarters beat the estimate; this quarter's +15.9% surprise compares with a +8.0% four-quarter average. Next scheduled report: 2026-10-26.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (-0.8% away)
- Euphoria warning: extreme positivity (+0.85) + overbought RSI 70
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $150.68
- Price target
- $173.28
- Stop
- $140.36
- Upside to target
- +15.0%
The stock trades at 69.0× trailing but 24.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 70 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
RVTY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $15.86B
- P/E (fwd)
- 24.1
- P/E (ttm)
- 69.0
- 52-week range
- $81.22–$149.52
- Off 52-week high
- -0.8%
- RSI (14)
- 70
- Volume vs avg
- 1.16×
- Score today
- 4.9/10